Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Peter Goss who wrote (4316)	11/19/2003 9:09:11 AM
From: Findit	Respond to of 37387

Pete looks like the late filing is a regular thing with them. Not too professional. Jim

To: Peter Goss who wrote (4316)	11/19/2003 4:42:22 PM
From: Patentlawmeister	Read Replies (3) \| Respond to of 37387

IMO, looks like an overreaction on the DRUG report ... lost a penny a share, about the same as last quarter, including depreciation, but rev's were up about 200K from the prior sequential (June 2003) quarter; you can't compare last year's quarter since they had a one time bulk sale of $3M ... cash is still pretty good at over $3M, so no dilution unlike other biotechs ... maybe people are reacting to the lawsuit against the former president for $3.5M owed to the company ... if they don't collect that, it's certainly a negative, plus the legal costs of the suit don't help. But it seems the long term prospects are unchanged by this report.